To assess the effectiveness of anti-arrhythmic drugs at promoting sinus rhythm in patients with atrial fibrillation by conducting a meta-analysis of randomised controlled trials (RCTs).
Methods of synthesis
How were the studies combined? The studies were combined in a repeated measures random-effects model. The five classes of drugs were compared on the two outcome measures. The inverse variance of the outcome measure estimate was used to weight the outcome measure at each time point. Least-square means and their 95% confidence interval (CIs) for the treatment difference were derived from the models at the median follow-up duration.
How were differences between studies investigated? Three sensitivity analyses were carried out on the sinus rhythm outcome variable: subgroup analyses were used to compare studies reporting a follow-up of less than one week to trials with at least one week' follow-up, and also to compare use of the drug intervention for conversion to as opposed to maintenance of sinus rhythm; the effects of using different study cohorts was assessed (further details provided in the paper); and the effect of study quality on the model was assessed. The latter two analyses were also carried out on the mortality data, in addition to an analysis based on the assumption that there was no death in studies not reporting mortality.
The effect of the class III drug amiodarone compared to any other anti-arrhythymic agent was assessed. The effect of including one large trial, which had a slightly different population from all the other studies, was also considered.
Results of the review
Ninety-one RCTs (n=8,563) were included.
Effect of anti-arrhythmic agents on sinus rhythm.
Class IA, IC and III drugs were associated with significant increases in the proportion of patients in sinus rhythm compared with placebo. In addition, the class IC drugs were associated with a significant increase in the proportion of patients in sinus rhythm compared with class IV drugs.
Compared with placebo, the mean treatment difference was 21.5% (95% CI: 16.3, 26.8, p<0.0001) for class IA drugs (7 trials), 33.1% (95% CI: 23.3, 42.9, p<0.0001) for class IC (17 trials), 17.4% (95% CI: 11.5, 23.3, p=0.001) for class III (19 trials), and 13.1% (95% CI: -7.2, 33.3, p=0.15) for digoxin (4 trials).
The mean treatment difference was 4.1% (95% CI: -8.0, 16.2, p=0.42) for class IA versus class III drugs (6 trials), -3.4% (95% CI: 17.2, 10.5, p=0.6) for class IC versus class III (10 trials), 43.2% (95% CI: 11.5, 75.0, p=0.03) for class IC versus class IV (4 trials), and 15.2% (95% CI : -43.7, 74.2, p=0.19) for class III versus digoxin (2 trials). There appears to be an error in the result for class IC versus class III drugs since the mean treatment difference (-3.4%) lies outside the confidence range reported (95% CI: 17.2, 10.5).
Effect of anti-arrhythmic agents on mortality.
There was no significant difference in mortality between active treatment and placebo, or between active treatment and comparison drug, for any of the classes of anti-arrhythmic drugs considered.
Compared with placebo, the mean treatment difference was 0.96% (95% CI: -0.45, 2.36, p<0.14) for class IA drugs (5 trials), -0.08% (95% CI: -0.20, 0.04, p<0.16) for class IC (14 trials), -0.11% (95% CI: -0.32, 0.09, p=0.25) for class III (17 trials), and 0.02% (95% CI: -0.01, 0.06, p=0.12) for digoxin (4 trials).
The mean treatment difference was 0.17% (95% CI: -0.58, 0.92, p=0.53) for class IA versus class III drugs (5 trials), -0.26% (95% CI: -1.10, 0.59, p=0.50) for class IC versus class III (8 trials), -0.06% (95% CI: -2.26, 2.13, p=0.91) for class IC versus class IV (4 trials), and 0.48% (95% CI: -13.71, 14.67, p=0.74) for class III versus digoxin (2 trials). the trials of class IC and class III drugs that followed patients up for less than 7 days. There was also an association between anti-arrhythmic drugs and increased sinus rhythm, compared with placebo, among the trials of class IA and class III drugs. When the large trial was included in the analysis, the results remained non significant. Also, the results were not altered when the analysis was adjusted for study quality or study cohorts. The results relating to mortality were not altered for any of the sensitivity analyses.
